Prolonged, But Not Diminished, Zidovudine Absorption Induced by a High‐Fat Breakfast
- 12 November 1994
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 14 (6) , 671-677
- https://doi.org/10.1002/j.1875-9114.1994.tb04159.x
Abstract
To determine the effect of a high-fat breakfast on single-dose, zidovudine (ZDV) pharmacokinetics. Open-label, randomized, crossover study. Eighteen asymptomatic subjects (12 men, 6 women) infected with the human immunodeficiency virus (mean CD4 cell counts of 512 +/- 178/mm3). Subjects received single 100-mg oral doses of ZDV as follows: after an 8-hour fast (treatment A), with a high-fat breakfast (treatment B), and 3 hours after a high-fat breakfast (treatment C). The high-fat breakfast significantly reduced the mean (coefficient of variation) maximum plasma concentration (Cmax) from 806 (55%) ng/ml with treatment A to 341 (47%) and 424 (42%) ng/ml with treatments B and C, respectively. The time to Cmax was significantly prolonged from 0.68 (30%) hours with treatment A to 1.7 (54%) and 1.3 (42%) hours with treatments B and C, respectively. Area under the plasma ZDV concentration-time curve (AUC) was not statistically different across the study treatments. Men had significantly lower (35%) renal clearances of both ZDV and its glucuronide metabolite than women. When ZDV was given either with or 3 hours after a high-fat breakfast, its absorption was prolonged and Cmax was reduced relative to fasting. However, systemic exposure, as indicated by AUC, was unchanged.This publication has 17 references indexed in Scilit:
- Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cellsAntimicrobial Agents and Chemotherapy, 1994
- Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDSAntimicrobial Agents and Chemotherapy, 1993
- Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedureAntimicrobial Agents and Chemotherapy, 1992
- Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patientsAntimicrobial Agents and Chemotherapy, 1992
- The effect of a protein meal on zidovudine pharmacokinetics in HIV‐ infected patients.British Journal of Clinical Pharmacology, 1992
- Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a mealEuropean Journal of Clinical Pharmacology, 1991
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat mealAIDS, 1990
- Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virusAntimicrobial Agents and Chemotherapy, 1989
- Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.Proceedings of the National Academy of Sciences, 1986